Wade Cooper, DO
Neurology · Ann Arbor, MINPI 1124007208
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $715,932 of the $990,518 with a category attached, or 72.3%. 21 manufacturers reported payments, led by AbbVie at 31.2% of the total. 2025 is the largest year on record at $376,154, 7.6 times the $49,345 reported in 2019. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,028 payments — averaging $963.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$309K
- Lundbeck LLC$256K
- Lilly USA, LLC$108K
- Pfizer$107K
- H. Lundbeck A S$89K
- Axsome Therapeutics, Inc.$56K
- plus $64K from 15 others
Across 16 payments — averaging $1461.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$23K
What the payments were for
- Consulting fees$203,14221%
- Speaking & faculty fees$715,93272%
- Travel & lodging$55,1016%
- Food & beverage$16,1692%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 277 | $308,851 |
| Lundbeck LLC | 290 | $256,494 |
| Lilly USA, LLC | 202 | $107,995 |
| Pfizer | 91 | $107,288 |
| H. Lundbeck A S | 40 | $89,301 |
| Axsome Therapeutics, Inc. | 39 | $56,452 |
| Teva Pharmaceuticals USA, Inc. | 29 | $20,878 |
| Eli Lilly | 9 | $15,521 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $7,165 |
| Amgen | 9 | $5,599 |
| Biohaven Pharmaceuticals, Inc. | 2 | $5,125 |
| Scilex Pharmaceuticals Inc. | 11 | $4,338 |
| Biodelivery Sciences International, Inc. | 1 | $3,000 |
| Tonix Medicines, Inc. | 1 | $2,000 |
| Eisai Inc. | 7 | $153 |
| Sumitomo Pharma America, Inc. | 6 | $110 |
| Upsher-smith Laboratories LLC | 1 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| SK Life Science, Inc. | 2 | $45 |
| Vertex | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$341,208
- QULIPTA$206,586
- UBRELVY$189,528
- NURTEC ODT$67,302
- ZAVZPRET$50,544
- BOTOX$50,000
- Symbravo$44,964
- EMGALITY$23,025
- AJOVY$20,474
- ELYXYB - CELECOXIB$7,200
- AIMOVIG$5,188
- REYVOW$2,256
- ZEMBRACE SYMTOUCH$2,000
- TOSYMRA$2,000
- ABILIFY MAINTENA$1,500
- REXULTI$1,500
- BRINTELLIX$1,500
How this compares
$990,518 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 60 | $94,181 |
| UbrelvyUbrogepant | 32 | $60,436 |
| Nurtec OdtRimegepant Sulfate | 29 | $42,487 |
| Emgality PenGalcanezumab-Gnlm | 46 | $39,203 |
| ZavzpretZavegepant Hcl | 25 | $29,673 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $18,471 |
| Sumatriptan Succinate | 85 | $10,627 |
| Lidocaine | 13 | $2,607 |
| Memantine Hcl | 105 | $1,746 |
| Gabapentin | 73 | $1,676 |
| Candesartan Cilexetil | 27 | $1,666 |
| Doxycycline Hyclate | 46 | $1,355 |
| Prazosin Hcl | 65 | $1,326 |
| Nebivolol Hcl | 27 | $1,251 |
| RizatriptanRizatriptan Benzoate | 68 | $1,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $308,851 | $154,61792 claims |
| PfizerNurtec Odt, Zavzpret | $107,288 | $72,16054 claims |
| Upsher-smith Laboratories LLCTopiramate | $95 | $85938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Ann Arbor
- James WeintraubAnn Arbor$194K
- Maysa HamadeAnn Arbor$90K
- Kelvin ChouAnn Arbor$52K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.